Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04071548
Other study ID # 46941
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 26, 2023
Est. completion date May 2024

Study information

Verified date March 2024
Source Stanford University
Contact Richard Reimer, MD
Phone 6504935000
Email rreimer@stanford.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Classification of activity tolerance is of importance in chronic progressive myopathies, not only to better understand functional implications of the disease state itself, but also for purposes of exercise prescription for health maintenance. Maximal exercise testing has been considered as the gold standard of assessing maximal aerobic capacity, however testing in individuals with neuromuscular disease is often limited due to pain, activity intolerance, musculoskeletal impairments, fatigue and other such related variables. Often, submaximal exercise testing can overcome some of these obstacles, and as such, is used frequently in the clinical environment. Non-ambulatory exercise testing utilizing an arm ergometer specifically has not been studied as heavily, especially in those with progressive myopathies. For this study, we will use maximal aerobic capacity testing for individuals with Cystinosis Myopathy utilizing a bike ergometer to allow testing of individuals regardless of their ambulatory status.


Description:

High Intensity Interval Training (HIIT) has been frequently used and studied in normal populations. HIIT exercise shows improved exercise capacity with possible benefits to the neuroendocrine system and neurotransmitters associated with well-being. In this study, we plan to compare aerobic capacity changes during seated HIIT aerobic exercise of individuals with Cystinosis Myopathy. Additionally, we will assess peripheral fatigue using quantitative strength force production and slope decline before and after HIIT aerobic training. High Intensity interval training: HIIT is a type of interval training that alternates between intense efforts and less intense recovery periods. Benefits include improved aerobic capacity, anaerobic energy, oxygen transport, lactate clearance and neuromuscular coordination. In this study, participants will train at maximal intensities (90-95% of VO2 Max) to place less strain on the neuromuscular system. The goal is to work at longer time periods above the lactate threshold causing an increase in blood lactate concentrations and improve muscles ability to oxidize fats and carbohydrates . Other studies have shown cardiovascular benefits of improved heart volume, maximal mitochondrial capacity and cardiac efficiency. HIIT training compared to regular moderate intensity exercise shows no difference in safety risk for individuals who are sedentary, have heart disease or stroke. However, compared to continuous exercise, HIIT appears to have improved oxygen consumption, blood vessel function, and glucose metabolism in healthy individuals . Methods: Ten participants who consent to participate in this exercise study, with no history or evidence of cardiomyopathy or conduction abnormality, and pass screening assessment for ability to complete the training program will be included and provided with an activity monitor, lower/upper extremity ergometer and remote fitness application that the participant will follow for the in-home training. This study will be a HIIT based home exercise program where participants will perform the lower extremity ergometer based on a HIIT protocol 3x week for 20-30 minutes for a total of 8 weeks. Baseline and end of training assessments will include MRI, muscle biopsy, strength and functional assessments including VO2 Max exercise testing and Timed Up and Go (TUG) tests. Participants will be provided hands on training to use the exercise ergometer, activity monitor, heart rate monitor, and exercise plan. The activity monitor will be programmed so that the researchers have access to monitor the patient's activity to ensure adherence to the program and changes in activity level. Additionally, a HIIT based fitness application will be installed on the participant's phone. The fitness application will be used as a guided exercise program and also allow the researchers a secondary method to monitor exercise adherence. The researchers will have access to the participant's Fitbit and fitness application use to monitor compliance. Participants who miss one session will be contacted by researchers as a reminder to follow the exercise plan. Skype sessions will be used as needed based on participant adherence or as needed for safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: >=18 years -<= 60 years male or female with documented diagnosis of Cystinosis Exclusion Criteria: All Cystinosis participants: - female subject who is known or suspected to be pregnant - excluded for other illnesses or medications that may impact growth, nutritional status, development, or bone health unrelated to cystinosis Exercise intervention: - exercise limitation due to pre-existing heart disease - individuals on medications that limit heart rate (beta adrenergic blockers) - unable to plantar flex or dorsiflex ankle against resistance - unable to use pedal ergometer

Study Design


Related Conditions & MeSH terms


Intervention

Other:
HIIT Exercise
HIIT exercise bike protocol 3 minute warm up Intervals of 10x 60 sec of 80-95% of heart rate reserve Heart rate reserve = Max Heart rate - Resting Heart rate § Max heart rate = 220-age 10x60 second Recovery period 5 minute cool-down

Locations

Country Name City State
United States Stanford University Palo Alto California

Sponsors (1)

Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

References & Publications (8)

Hafstad AD, Boardman NT, Lund J, Hagve M, Khalid AM, Wisloff U, Larsen TS, Aasum E. High intensity interval training alters substrate utilization and reduces oxygen consumption in the heart. J Appl Physiol (1985). 2011 Nov;111(5):1235-41. doi: 10.1152/japplphysiol.00594.2011. Epub 2011 Aug 11. — View Citation

Helou K, El Helou N, Mahfouz M, Mahfouz Y, Salameh P, Harmouche-Karaki M. Validity and reliability of an adapted arabic version of the long international physical activity questionnaire. BMC Public Health. 2017 Jul 24;18(1):49. doi: 10.1186/s12889-017-4599-7. Erratum In: BMC Public Health. 2017 Sep 22;17 (1):736. — View Citation

Hood MS, Little JP, Tarnopolsky MA, Myslik F, Gibala MJ. Low-volume interval training improves muscle oxidative capacity in sedentary adults. Med Sci Sports Exerc. 2011 Oct;43(10):1849-56. doi: 10.1249/MSS.0b013e3182199834. — View Citation

Jelleyman C, Yates T, O'Donovan G, Gray LJ, King JA, Khunti K, Davies MJ. The effects of high-intensity interval training on glucose regulation and insulin resistance: a meta-analysis. Obes Rev. 2015 Nov;16(11):942-61. doi: 10.1111/obr.12317. — View Citation

Milanovic Z, Sporis G, Weston M. Effectiveness of High-Intensity Interval Training (HIT) and Continuous Endurance Training for VO2max Improvements: A Systematic Review and Meta-Analysis of Controlled Trials. Sports Med. 2015 Oct;45(10):1469-81. doi: 10.1007/s40279-015-0365-0. — View Citation

Silsbury Z, Goldsmith R, Rushton A. Systematic review of the measurement properties of self-report physical activity questionnaires in healthy adult populations. BMJ Open. 2015 Sep 15;5(9):e008430. doi: 10.1136/bmjopen-2015-008430. — View Citation

Tsampalieros A, Gupta P, Denburg MR, Shults J, Zemel BS, Mostoufi-Moab S, Wetzsteon RJ, Herskovitz RM, Whitehead KM, Leonard MB. Glucocorticoid effects on changes in bone mineral density and cortical structure in childhood nephrotic syndrome. J Bone Miner Res. 2013 Mar;28(3):480-8. doi: 10.1002/jbmr.1785. — View Citation

Wetzsteon RJ, Kalkwarf HJ, Shults J, Zemel BS, Foster BJ, Griffin L, Strife CF, Foerster DL, Jean-Pierre DK, Leonard MB. Volumetric bone mineral density and bone structure in childhood chronic kidney disease. J Bone Miner Res. 2011 Sep;26(9):2235-44. doi: — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary VO2 max testing Patients will undergo exercise stress testing using a recumbent cycle ergometry pre and post exercise intervention: Baseline and after week 12. We will use a ramping protocol to maintain a pedal cadence between 50-80RPM which will yield progressive workload increments of 5-10 Watts. Participants will be continuously monitored for any discomfort or pain that they may experience. Maximal effort will be verified as volitional fatigue (OMNI Scale=8, the inability to maintain pedal cadence at 50 rpm for 10 or more seconds, and/or respiratory exchange ratio (RER; carbon dioxide production/oxygen uptake)>1.0). Standard ACSM exercise termination criteria will be applied. Measurements will end immediately following exercise. Using this method, peak oxygen uptake (VO2peak) will be identified as the highest oxygen uptake measured during exercise. 30-45 minutes
Secondary Biodex Quantiive muscle testing Biodex isokinetic dynamometer is used for testing strength throughout an entire arc of range of motion. It is commonly used to assess strength and well validated in the orthopedic field. Patients will undergo testing of both knee extensors and flexors strength as part of this protocol. Each participant will be tested in a seated position with hip flexion at 110-125 degrees; stabilization straps will be applied at the trunk and thighs. The resistance pad will be placed proximally at the medial malleolus. Range of motion at the knee will be set from 0-90 degrees. Vocal encouragement will be provided during the test and standardized for consistency between measures. Average power and H/Q ratios will be calculated and reported by the Biodex. 30 minutes
Secondary Timed up and Go (TUG) Test This is a functional timed test requiring the participant to get up from a chair walk 3 meters and sit back down in the chair. It has been used to asses function and balance. 5 minutes
Secondary Activity Monitor We will use an activity monitor to be worn by the participant throughout the trial. For this study, participants will be issued fitbit that will estimate characteristics of physical activity. The activity monitor will help determine adherence to the exercise intervention via monitoring of the clinical research team for increased exercise at times and frequencies indicated by the protocol. Additionally, this will give us a measurable tool to assess possible changes in activity while on the study. We will compare baseline measures to changes at the end of the 12 week intervention program. 24 hours
Secondary Activity Questionnaire We will conduct a the International Physical Activity Questionnaire (IPAQ). It is developed to assess physical activity and sedentary lifestyle among people 15-69 years old. There are 5 activity domains that should be answered based on activity in the last 7 days. It has 3 categorical levels of scoring with 1 being low and 3 high. It will be provided to all participants before the start of the intervention, 8 weeks and 12 weeks. This questionnaire will help determine any changes in behavior or activity during the exercise intervention period. The questionnaire asks about amount of time the participant participates in organized sports, gym, outdoor activities, and physical exercise. This activity monitor has been used in a Cystinosis natural history study. 5 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT05545774 - Neuromuscular Characterisation in Late Adolescent and Adult Cystinosis Patients
Completed NCT01432561 - Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagonâ„¢ N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT04125927 - Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2) Phase 3
Completed NCT00071903 - The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study N/A
Recruiting NCT05994534 - PK and PD Study of NPI-001 and Cysteamine Bitartrate Phase 1/Phase 2
Completed NCT00004312 - Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis N/A
Completed NCT00004350 - Evaluation of Fanconi Syndrome and Cystinosis N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Completed NCT02533076 - The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients Phase 0
Enrolling by invitation NCT05146830 - A Long-Term Follow-Up Study of Participants With Cystinosis Who Previously Received CTNS-RD-04
Completed NCT00872729 - Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis Phase 1/Phase 2
Completed NCT00001736 - New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis Phase 1
Recruiting NCT05959668 - Development of Health-related Quality of Life Instrument for Patients With Cystinosis
Withdrawn NCT02124070 - Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis Phase 1/Phase 2
Completed NCT01614431 - N Acetyl Cysteine for Cystinosis Patients Phase 4
Recruiting NCT05843851 - Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria N/A
Completed NCT01000961 - Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis Phase 3
Active, not recruiting NCT03897361 - Stem Cell Gene Therapy for Cystinosis Phase 1/Phase 2